Loading...
XJPX4536
Market cap3.37bUSD
Dec 25, Last price  
1,565.50JPY
1D
2.70%
1Q
-11.04%
Jan 2017
11.54%
Name

Santen Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XJPX:4536 chart
P/E
19.52
P/S
1.72
EPS
80.21
Div Yield, %
2.28%
Shrs. gr., 5y
-2.01%
Rev. gr., 5y
5.23%
Revenues
301.97b
+8.22%
92,696,000,00098,397,000,000100,485,000,000103,394,000,000101,618,000,000110,594,000,000110,812,000,000114,416,000,000119,066,000,000148,663,000,000161,831,000,000195,291,000,000199,096,000,000224,942,000,000234,026,000,000241,555,000,000249,605,000,000266,257,000,000279,037,000,000301,965,000,000
Net income
26.64b
P
11,022,000,00013,022,000,00013,147,000,00012,650,000,00010,123,000,00018,722,000,00021,333,000,00017,160,000,00016,520,000,00017,109,000,00024,032,000,00053,373,000,00023,054,000,00035,261,000,00031,943,000,00023,618,000,0006,830,000,00027,218,000,000-14,948,000,00026,642,000,000
CFO
72.65b
+95.57%
6,619,000,00020,878,000,00014,959,000,00015,468,000,00011,849,000,00026,110,000,00017,769,000,00021,483,000,0009,942,000,00025,958,000,00025,386,000,00022,525,000,00010,843,000,00042,843,000,00032,894,000,00039,947,000,00038,808,000,00046,043,000,00037,147,000,00072,649,000,000
Dividend
Mar 28, 20250 JPY/sh
Earnings
Feb 06, 2025

Profile

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
URL
https://www.santen.co.jp/ja/
IPO date
Nov 04, 1963
Employees
4,144
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
301,965,000
8.22%
279,037,000
4.80%
266,257,000
6.67%
Cost of revenue
250,775,000
237,504,000
220,547,000
Unusual Expense (Income)
NOPBT
51,190,000
41,533,000
45,710,000
NOPBT Margin
16.95%
14.88%
17.17%
Operating Taxes
3,171,000
9,184,000
8,427,000
Tax Rate
6.19%
22.11%
18.44%
NOPAT
48,019,000
32,349,000
37,283,000
Net income
26,642,000
-278.23%
(14,948,000)
-154.92%
27,218,000
298.51%
Dividends
(11,881,000)
(12,607,000)
(11,994,000)
Dividend yield
2.10%
2.88%
2.44%
Proceeds from repurchase of equity
(16,962,000)
(13,780,000)
(20,472,000)
BB yield
3.00%
3.15%
4.17%
Debt
Debt current
2,748,000
3,056,000
13,965,000
Long-term debt
41,756,000
33,151,000
18,967,000
Deferred revenue
(9,346,000)
7,277,000
11,161,000
Other long-term liabilities
(652,000)
1,311,000
947,000
Net debt
(74,863,000)
(65,030,000)
(92,319,000)
Cash flow
Cash from operating activities
72,649,000
37,147,000
46,043,000
CAPEX
(10,687,000)
(24,588,000)
(35,841,000)
Cash from investing activities
(6,145,000)
(26,777,000)
(35,169,000)
Cash from financing activities
(34,031,000)
(37,220,000)
5,557,000
FCF
54,560,000
17,525,000
24,401,000
Balance
Cash
94,961,000
58,677,000
84,307,000
Long term investments
24,406,000
42,560,000
40,944,000
Excess cash
104,268,750
87,285,150
111,938,150
Stockholders' equity
248,121,000
540,069,000
635,992,000
Invested Capital
240,005,250
239,790,850
260,101,850
ROIC
20.02%
12.94%
15.34%
ROCE
14.81%
12.66%
12.22%
EV
Common stock shares outstanding
368,139
387,420
400,457
Price
1,536.50
35.97%
1,130.00
-7.91%
1,227.00
-19.44%
Market cap
565,645,574
29.21%
437,784,600
-10.90%
491,360,739
-19.42%
EV
490,097,574
628,269,600
706,198,739
EBITDA
69,368,000
58,782,000
62,765,000
EV/EBITDA
7.07
10.69
11.25
Interest
2,664,000
1,499,000
1,209,000
Interest/NOPBT
5.20%
3.61%
2.64%